FY2027 EPS Estimates for Liquidia Increased by HC Wainwright

Liquidia Corporation (NASDAQ:LQDA) – HC Wainwright lifted their FY2027 EPS estimates for Liquidia in a note issued to investors on Thursday, July 23rd. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of $7.12 for the year, up from their prior forecast of $5.94. The consensus estimate for Liquidia’s current full-year earnings is $3.02 per share. HC Wainwright also issued estimates for Liquidia’s FY2028 earnings at $7.77 EPS, FY2029 earnings at $9.29 EPS and FY2030 earnings at $11.12 EPS.

Several other analysts also recently weighed in on the company. Needham & Company LLC raised their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Stephens set a $130.00 price target on Liquidia in a research note on Friday. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 price target on shares of Liquidia in a research note on Thursday, June 4th. Oppenheimer set a $75.00 price objective on Liquidia in a research note on Friday, June 5th. Finally, BTIG Research upped their target price on Liquidia from $59.00 to $109.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $86.18.

Liquidia Stock Performance

Shares of LQDA stock opened at $86.82 on Monday. Liquidia has a 12 month low of $16.82 and a 12 month high of $91.10. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm has a market capitalization of $7.72 billion, a P/E ratio of 620.19 and a beta of 0.55. The company’s fifty day moving average price is $72.31 and its two-hundred day moving average price is $50.98.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia’s revenue for the quarter was up 4187.1% compared to the same quarter last year.

Insider Transactions at Liquidia

In related news, Director Stephen M. Bloch sold 318,893 shares of Liquidia stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $50.23, for a total value of $16,017,995.39. Following the completion of the transaction, the director directly owned 1,870,042 shares in the company, valued at approximately $93,932,209.66. This trade represents a 14.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul B. Manning sold 200,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the sale, the director directly owned 716,311 shares of the company’s stock, valued at approximately $45,779,436.01. This represents a 21.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 2,198,466 shares of company stock valued at $144,724,339 over the last quarter. Insiders own 25.60% of the company’s stock.

Hedge Funds Weigh In On Liquidia

Several large investors have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the fourth quarter valued at $25,000. Covestor Ltd lifted its position in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares during the last quarter. NewEdge Advisors LLC bought a new position in shares of Liquidia in the 2nd quarter worth about $25,000. Fluent Financial LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at about $287,000. Finally, Fulcrum Equity Management acquired a new position in shares of Liquidia in the 2nd quarter valued at about $399,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: LifeSci Capital maintained its Buy rating on Liquidia, supporting the bullish view of the company’s outlook. LifeSci Capital Sticks to Their Buy Rating for Liquidia
• Positive Sentiment: HC Wainwright expressed a positive view of Liquidia’s fiscal 2027 earnings prospects, suggesting analysts expect meaningful future growth. HC Wainwright Has Positive View of Liquidia FY2027 Earnings
• Positive Sentiment: Buckley Capital Advisors said Liquidia could have more than 50% upside, citing the upcoming YUTREPIA ruling and potential buyout interest. This reinforces the importance of regulatory and strategic catalysts for LQDA. Liquidia Has 50% Plus Upside on YUTREPIA Ruling and Buyout Potential
• Neutral Sentiment: Recent valuation coverage highlights a debate between YUTREPIA-driven growth and patent risk. Another analysis argues the stock still looks expensive as YUTREPIA expansion progresses, indicating that further appreciation depends on execution and successful intellectual-property outcomes. Liquidia Rallies as Fair Value Debate Turns on Growth and Patent Risk Liquidia Stock Still Looks Expensive
• Negative Sentiment: Director Stephen M. Bloch disclosed three sales totaling 178,596 shares for approximately $15.2 million between July 20 and July 23. Although he retained a substantial position, the sizable reduction could weigh on sentiment because it signals insider profit-taking after LQDA’s strong run. SEC Insider Transaction Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).